In the next month or two NeoStem should announce complete enrollment. Then, we are just six months away from Phase 2 data. This will be a point where the market will assess the product's strong data to date, and more AMR-001/Baxter comparisons will be made. Expect a predata run-up, and if data is good, expect Baxter to #$%$ up NeoStem fast.
Baxter's own phase 3 CD34+ trial was announced 28 Feb 12. From their press release.
"The trial will enroll approximately 450 patients across 50 clinical sites in the United States, who will be randomized to one of three arms: treatment with their own autologous CD34+ stem cells, treatment with placebo (control), or unblinded standard of care. The primary objective is to evaluate the efficacy of treatment with CD34+ stem cells to improve the functional capacity of patients with CMI, as measured by a change in total exercise capacity at 12 months following treatment. Secondary objectives include reduced frequency of angina episodes at 12 months after treatment and the safety of targeted delivery of the cells."
Baxter's treatment and goals differ from NeoStem's current phase 2 trial, but one would think NBS would benefit from positive Baxter results. Assuming Baxter completed enrollment during 2012, results should be released early 2014.